Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ∼35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“Moreover, the potential applications of vaccines have broadened greatly as the biological implications of immunology have extended from infectious diseases, allergy and autoimmunity to metabolic disease 3 , neuro-degeneration 4 and cancer 5 .”
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“Moreover, the potential applications of vaccines have broadened greatly as the biological implications of immunology have extended from infectious diseases, allergy and autoimmunity to metabolic disease 3 , neuro-degeneration 4 and cancer 5 .”
Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences
Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C. J. L., Furman, D., Shen-Orr, S., Dekker, C. L., Swan, G. E., Butte, A. J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.020 · Cited by 1,065
Causes, consequences, and reversal of immune system aging
Montecino-Rodriguez, E., Berent-Maoz, B., & Dorshkind, K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64096 · Cited by 793 · cited 2×
“This study was not designed to explore the well-established compromise in adaptive responses in subjects aged over 70 27,28 .”
Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines
Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S., Lalor, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.020 · Cited by 601 · cited 1×
“In that regard, the early enrichment for HLA-DR + CD38 + activated effector T cells in the HIRD trial contrasted somewhat with delayed increases in those cells following smallpox or Yellow Fever vaccination 35,36 .”
The Vaccine Adverse Event Reporting System (VAERS)
CHEN, R., RASTOGI, S., MULLEN, J., HAYES, S., COCHI, S., DONLON, J., & WASSILAK, S. (1994) · Vaccine · doi:10.1016/0264-410x(94)90315-8 · Cited by 498
Human T Cell Aging and the Impact of Persistent Viral Infections
Fülöp, T., Larbi, A., & Pawelec, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00271 · Cited by 347 · cited 1×
“Age is a fundamental component of experiential variation, and marked declines in adaptive responsiveness in the elderly are well known and increasingly well understood 7,27,39,40 .”
Lineage Structure of the Human Antibody Repertoire in Response to Influenza Vaccination
Jiang, N., He, J., Weinstein, J. A., Penland, L., Sasaki, S., He, X.-S., Dekker, C. L., Zheng, N.-Y., Huang, M., Sullivan, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004794 · Cited by 335 · cited 1×
“This study was not designed to explore the well-established compromise in adaptive responses in subjects aged over 70 27,28 .”
Duffy, D., Rouilly, V., Libri, V., Hasan, M., Beitz, B., David, M., Urrutia, A., Bisiaux, A., LaBrie, S. T., Dubois, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.002 · Cited by 242 · cited 4×
“Thus, several studies have shown that many immunological metrics show little day-to-day variation 7,8 , thereby permitting reliable measurements of their responses to scheduled perturbations such as vaccination 6 , immune checkpoint-blockade 9 , or iatrogenic immune-suppression 10 .”
InfluentialApoptosis and other immune biomarkers predict influenza vaccine responsiveness
Furman, D., Jojic, V., Kidd, B., Shen‐Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H. T., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.15 · Cited by 184 · cited 6×
“Importantly, and in contrast to flu vaccines used in American immune-monitoring studies 8,13,15,16,17 , the UK H1N1 Pandemrix vaccine included an adjuvant, AS03, designed to enhance immunogenicity 18,19 .”
Influential
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
A dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946
Self-citationBrodin, P., & Davis, M. M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2016.125 · Cited by 730
Stereotypic Immune System Development in Newborn Children
Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J., Gustafsson, A., Bernhardsson, A. K., Zhang, C., Bohlin, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.045 · Cited by 696
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
The how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
“Correspondingly, type I interferon mRNA is usually unrecordable in peripheral blood from healthy individuals, even after vaccination (Sobolev et al., 2016), or in patients with putative type I interferonopathies.”
BackgroundAIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies
Meyer, S., Woodward, M., Hertel, C., Vlaicu, P., Haque, Y., Kärner, J., Macagno, A., Onuoha, S. C., Fishman, D., Peterson, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.024 · Cited by 292
Self-citationMetabolic Phenotypes of Response to Vaccination in Humans
Li, S., Sullivan, N. L., Rouphael, N., Yu, T., Banton, S., Maddur, M. S., McCausland, M., Chiu, C., Canniff, J., Dubey, S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.026 · Cited by 276
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
Pifferi, C., Fuentes, R., & Fernández-Tejada, A. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-020-00244-3 · Cited by 265
Harnessing the beneficial heterologous effects of vaccination
Goodridge, H. S., Ahmed, S. S., Curtis, N., Kollmann, T. R., Levy, O., Netea, M. G., Pollard, A. J., van Crevel, R., & Wilson, C. B. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.43 · Cited by 258
New-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 190
Human immune diversity: from evolution to modernity
Liston, A., Humblet-Baron, S., Duffy, D., & Goris, A. (2021) · Nature Immunology · doi:10.1038/s41590-021-01058-1 · Cited by 187
Metadata
- Authors
- Sobolev, O., Binda, E., O'Farrell, S., Lorenc, A., Pradines, J., Huang, Y., Duffner, J., Schulz, R., Cason, J., Zambon, M., Malim, M. H., Peakman, M., Cope, A., Capila, I., Kaundinya, G. V., & Hayday, A. C.
- Venue
- Nature Immunology
- Published
- 2016-01-04
- Volume
- 17
- Issue
- 2
- Pages
- 204-213
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2233571397
- Cited by
- 149
- References
- 11
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.